Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05813717 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants | PHASE1 | COMPLETED | 25 | — | — | Apr 10, 2023 | Oct 2, 2023 | Nov 7, 2023 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort J1 | EXPERIMENTAL | - |
| Cohort J2 | EXPERIMENTAL | - |
| Cohort J3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986325 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be ethnically Japanese (both biological parents are ethnically Japanese). * Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory de...